The therapeutic approach of ‘reactivating p53’ (e.g. by MDM2 antagonists, or delivery of wild type p53) for neuroblastoma, which develops in the context of MYCN-mediated p53 repression is an active area of investigation with several early phase clinical trials underway [58], [59]. The gene discussed is MDM2; the disease is neuroblastoma.